@RossFirestone profile picture
Ross Firestone @RossFirestone

Physician scientist @MSKCancerCenter via @DOMSinaiNYC @einstein_mstp

Joined April 2023
  • Tweets 26
  • Following 166
  • Followers 234
8 Photos and videos
Ross Firestone retweeted
Robert Z. Orlowski@Myeloma_Doc
May 2
#Myeloma Paper of the Day: A differentiated T-cell repertoire (CD8 CD45RA CD62L-CCR7- T effector cells re-expressing CD45RA (TEMRA)) may define a functionally high-risk group (median time to progression of 2.1 years) of smoldering myeloma patients: pubmed.ncbi.nlm.nih.gov/4206…. #mmsm
5
15
28
6,201
Ross Firestone retweeted
OncoDaily
@oncodaily
26 Aug 2025
Myeloma Paper of the Day, August 26th, Suggested by Robert Orlowski (@Myeloma_Doc) @RossFirestone @DrOlaLandgren @szusmani @LesokhinMD oncodaily.com/science/myelom… #OncoDaily #Oncology #Cancer #Health #Medicine #MedTwitter #MedEd #MedOnc #MedNews #MM #Myeloma @CancerWorldmag
3
11
755
Ross Firestone retweeted
Robert Z. Orlowski@Myeloma_Doc
26 Aug 2025
#Myeloma Paper of the Day: Immune-MRD status informs tumor-MRD outcome prognostication in myeloma pts on Len maintenance; T cell profiles enriched w/ activated cytotoxic effectors predict early relapse & quiescent/naïve T-cells predicting remission: pubmed.ncbi.nlm.nih.gov/4085…. #mmsm
1
15
36
13,379
Ross Firestone retweeted
Francesco Maura@FrancescoMaura4
27 Jun 2025
It was fun to work with @RossFirestone in writing this editorial for @BloodPortfolio #Blood "More than myeloma: the trouble with “normal” plasma cells", on the recent article from @nickbolli @matteoclaudio84 sciencedirect.com/science/ar… @MSKCancerCenter @MSK_DeptOfMed #mmsm

1
7
16
2,873
Ross Firestone retweeted
Anish Simhal@aksimhal
21 Feb 2025
1/ 🚨New research alert! 🚨Our study in @BloodCancerJnl shows that high WEE1 expression is an independent predictor of poor survival in multiple myeloma (MM), with @RossFirestone, @MalinHultcrantz, @LarryNortonMD, @szusmani, and the rest of the @MSKCancerCenter team! 🧵👇
2
5
18
1,981
Ross Firestone retweeted
Blood Journals Portfolio@BloodPortfolio
29 Jul 2024
Therapy–mediated BCMA expression loss after belantamab or anti-BCMA chimeric antigen receptor T cells underlies teclistamab failure in RRMM. ow.ly/sarP50SM9ys #lymphoidneoplasia #immunobiologyandimmunotherapy #multiplemyeloma
1
12
27
4,317
Our work with @szusmani and @DavidJChungMD at @MSKCancerCenter looking at antigen escape with BCMA-targeting therapies in #MMSM patients is now out in @BloodJournal authors.elsevier.com/a/1jUXn… 1/7

3
11
34
5,112
more replies
We also found that, at times of active disease, low or undetectable levels of soluble BCMA reported on expression loss, offering a noninvasive method to test BCMA expression in clinical practice settings 6/7
1
5
362
Thanks to the investigators and to our patients for help with this work! 7/7
2
249
Conclusion: We need to do a better job preparing patients for the expected complications of BsAb and CAR T therapies (both major and minor) to avoid unnecessary healthcare interactions and improve QoL, while still keeping patients safe. 5/6
1
2
4
683
We also can't ignore that remote healthcare utilization is part of the patient experience. Portal messages and phone calls, while not as burdensome as in-person visits, are important signals of patient unease. #rUHI 6/6
2
5
721
In this study we looked at unscheduled healthcare interactions in MM patients receiving CAR T or BsAbs, with a focus on remote interactions. We found that healthcare utilization was high, even in patients responding well to treatment. 2/6
1
2
3
840
more replies
Notably, unscheduled interactions rarely altered treatments plans, and patients almost always went home from in-person visits without care escalation. 4/6
1
1
234
Remote and in-person healthcare utilization was higher in BsAb patients, seemingly due to an increased incidence of low-risk infections (URIs, etc). 3/6
1
3
5
642
Excited to see our manuscript on healthcare utilization in CAR T and bispecifics patients with #MMSM in press! This work was spearheaded by Anna Howard RN and @isabelconcepci MSN FNP-C. ashpublications.org/bloodadv… 1/6

Unscheduled health care interactions in patients with multiple myeloma receiving T-cell redirection...

Key PointsPatients with MM receiving BsAbs or CAR T-cell therapies require frequent UHIs.BsAb patients had more frequent unscheduled health care interactio

ashpublications.org
4
10
28
2,619
Happy to see my first research paper of fellowship is officially in press! So, of course, it’s time for my first ever tweet discussing observations in real-world #Teclistamab patients with #MMSM! (ashpublications.org/bloodadv……) A quick thread 1/6

Blood Advances | American Society of Hematology

Blood Advances is a semimonthly medical journal published by the American Society of Hematology. It is the first Journal to join the Blood family in 70 years and is a peer-reviewed, online only, open...

ashpublications.org
7
14
59
11,068
more replies
Lots of work still to do (stay tuned!) but these findings, along with work from other groups, show that immune status may be critical for response to bispecifics like Tec  6/6
2
7
860
Link to paper here! ashpublications.org/bloodadv…

CD8 effector T cells enhance teclistamab response in BCMA-exposed and -naïve multiple myeloma

Teclistamab is effective in real-world patients with R/RMM, including those with prior anti-BCMA therapy exposure, albeit with slightly poorer progression-

ashpublications.org
3
3
12
1,136
Load more